Short Interest in Caring Brands, Inc. (NASDAQ:CABR) Rises By 281.9%

Caring Brands, Inc. (NASDAQ:CABR) was the recipient of a large increase in short interest in August. As of August 31st, there was short interest totaling 23,442 shares, an increase of 281.9% from the August 15th total of 6,138 shares. Based on an average daily volume of 31,051 shares, the short-interest ratio is presently 0.8 days. Currently, 0.3% of the shares of the stock are sold short.

Institutional Investors Weigh In On Caring Brands

An institutional investor recently bought a new position in Caring Brands stock. Jane Street Group LLC bought a new position in Caring Brands, Inc. (NASDAQ:CABR) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm bought 34,446 shares of the company’s stock, valued at approximately $30,000. Jane Street Group LLC owned approximately 0.25% of Caring Brands at the end of the most recent reporting period.

Analyst Ratings Changes

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Caring Brands in a research report on Tuesday. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company currently has a consensus rating of “Sell”.

Caring Brands Price Performance

Caring Brands stock traded up $0.05 during midday trading on Friday, reaching $1.19. The company had a trading volume of 39,852 shares, compared to its average volume of 43,777. The company has a market capitalization of $12.34 million and a P/E ratio of -1.61. Caring Brands has a 12-month low of $0.71 and a 12-month high of $5.35. The firm’s fifty day simple moving average is $1.37 and its 200-day simple moving average is $1.18. The company has a debt-to-equity ratio of 0.03, a current ratio of 4.96 and a quick ratio of 4.93.

Caring Brands (NASDAQ:CABR) last posted its quarterly earnings data on Thursday, August 13th. The company reported ($0.10) EPS for the quarter.

About Caring Brands

We are a wellness consumer products company. We offer several over-the-counter, or (OTC) and cosmetic, consumer products. Our method of operation is to ensure that (1) the mechanism of action of all products is established, (2) efficacy is determined through controlled clinical trials, (3) products are protected by issued and filed patents, and (4) products have acceptable commercial stability. Prior to its Q3 2022 commercial launch in India as a treatment for vitiligo and psoriasis, Photocil was briefly launched in the United States markets from December 2022 until February 2023, however, was subsequently removed from the market due to insufficient sales resulting from the lack of a dedicated sales and marketing team.